ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
Experienced hematologist-oncologist to lead strategic and medical oversight of clinical development program
Article content
SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the 'Company') (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company's leadership team as Chief Medical Officer ('CMO'), effective July 14, 2025.
Article content
Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS' clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial.
Article content
'Dr. Stakiw brings a wealth of clinical expertise and firsthand patient experience in oncology care, which is instrumental as we advance our Phase 2 UTOPIA trial,' said Brent Zettl, President and CEO of ZYUS. 'Her strong understanding of research and treatment development will be invaluable in addressing the critical need for effective, non-opioid cancer pain therapies and supporting our commitment to improving patient outcomes.'
Article content
'I'm pleased to take on the role of Chief Medical Officer at ZYUS,' said Dr. Julie Stakiw. 'ZYUS' commitment to developing innovative, non-opioid alternatives for cancer pain aligns with my passion for improving patient care. I look forward to contributing my clinical and research experience to support the advancement of the Phase 2 UTOPIA trial and help bring meaningful new options to patients facing cancer pain.'
Article content
Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by specialized training in hematology at Queen's University and a clinical fellowship in lymphoma and stem cell transplantation at Princess Margaret Hospital in Toronto. She has held several key leadership positions including Provincial Leader of Hematology, Medical Director of Saskatchewan's Blood and Marrow Transplant Program, and Medical Director of the Saskatoon Cancer Clinic. Dr. Stakiw also previously served as Director of Clinical Trials at a regional cancer centre in Ontario and as Director of Patient Research and Innovation for the Saskatchewan Cancer Agency. Known for her patient-centered approach and expertise in managing complex hematologic conditions such as multiple myeloma and leukemia, Dr. Stakiw continues to serve as a Clinical Professor in Hematological Oncology at the University of Saskatchewan while maintaining an active clinical practice. Her extensive clinical and leadership experience will be instrumental in advancing ZYUS' clinical development program.
Article content
Dr. Stakiw succeeds Dr. Lionel Marks de Chabris, who is stepping down as CMO and will continue to provide strategic guidance as Chair of the Clinical Research Advisory Committee. The Company is grateful for Dr. Marks de Chabris's ongoing leadership and commitment to advancing ZYUS' mission.
Article content
About ZYUS Life Sciences Corporation
Article content
ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X @ZYUSCorp.
Article content
Cautionary Note Regarding Forward-Looking Statements
Article content
This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin® softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin® softgel capsules and build shareholder value. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin® softgel capsules, introduce products that act as alternatives to current pain management therapies, advance Phase 2 clinical development of Trichomylin® softgels, and build shareholder value are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies or advance Phase 2 clinical development of Trichomylin® softgels. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
For more information, please contact:
Article content
ZYUS Media Inquiries
media@zyus.com
1-833-651-7723
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Trident Resources Announces Disposition of Lincoln Gold Mining Inc. Shares
Vancouver, BC, July 15, 2025 (GLOBE NEWSWIRE) -- Trident Resources Corp. (TSX-V: ROCK ) (OTCQB: TRDTF ) ('Trident' or the 'Company') announces the disposition of securities of Lincoln Gold Mining Inc. ("Lincoln") (TSXV: LMG) on the TSX Venture Exchange. On July 14, 2025 and July 15, 2025, Trident disposed of 4,500,000 common shares (the 'Subject Shares') of Lincoln. The Subject Shares represented approximately 19.9% of all issued and outstanding common shares of Lincoln as of July 15, 2025 (22,559,831 per Lincoln's MD&A dated May 30, 2025), immediately following the transaction described above, resulting in a corresponding decrease in the percentage of shares held by Trident as a result of the transaction. Immediately before the transaction described above, Trident held 4,500,000 common shares of Lincoln (the 'Pre-Shares'), representing approximately 19.9% of the issued and outstanding common shares of Lincoln. Immediately following the transaction described above, Trident held 0 common shares of Lincoln (the 'Post-Shares'), representing approximately 0% of the issued and outstanding common shares of Lincoln. The Subject Shares were sold at a price of $0.20 per Subject Share, for an aggregate consideration of $900,000. The holdings of securities of Lincoln by Trident are managed for investment purposes. Trident may from time to time acquire additional securities of Lincoln, dispose of some or all of the existing or additional securities they hold or will hold, or may continue to hold their current positions. A copy of the applicable securities report filed in connection with the matters set forth above may be obtained on SEDAR+ under the profiles of the Company and Lincoln. About Trident Resources Corp.: Trident Resources Corp. is a Canadian public mineral exploration company listed on the TSX Venture Exchange focused on the acquisition, exploration and development of advanced-stage gold and copper exploration projects in Saskatchewan, Canada. The Company is advancing its 100% owned Contact Lake and Greywacke Lake projects which host significant historical gold resources located within the prospective and underexplored La Ronge Gold Belt, as well as the 100% owned Knife Lake copper project which contains a historical copper resource. Trident's Project Portfolio Map: To find out more about Trident Resources Corp. (TSX-V: ROCK), visit the Company's website at Trident Resources Corp. Jonathan Wiesblatt, Chief Executive Officer Email: For further information contact myself or: Andrew J. Ramcharan, PhD, Corporate Communications Trident Resources Corp. Telephone: 647-309-5130 Toll Free: 800-567-8181 Facsimile: 604-687-3119 Email: info@ NEITHER THE TSXV NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE. Forward-Looking Information and Statements This release includes certain statements that may be deemed to be "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, regulatory approvals, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at for further information. This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Globe and Mail
25 minutes ago
- Globe and Mail
RioCan Real Estate Investment Trust Announces July 2025 Distribution
RioCan Real Estate Investment Trust ('RioCan') (TSX: today announced a distribution of 9.65 cents per unit for the month of July. The distribution will be payable on August 8, 2025, to unitholders of record as at July 31, 2025. About RioCan RioCan is one of Canada's largest real estate investment trusts. RioCan owns, manages and develops retail-focused, mixed-use properties located in prime, high-density transit-oriented areas where Canadians want to shop, live and work. As at March 31, 2025, our portfolio is comprised of 177 properties with an aggregate net leasable area of approximately 32 million square feet (at RioCan's interest). To learn more about us, please visit
National Post
28 minutes ago
- National Post
Largo Reports Improved Q2 2025 Vanadium Production; Storion Energy to Support 48 MWh Vanadium Flow Battery Deployment in Texas
Article content Article content TORONTO — Largo Inc. (' Largo ' or the ' Company ') (TSX: LGO) (NASDAQ: LGO) today announces quarterly production of 2,256 tonnes of vanadium pentoxide (' V₂O₅ ') equivalent and sales of 1,807 tonnes in Q2 2025, highlighting improved production and ongoing turnaround execution. Article content Daniel Tellechea, Interim CEO of Largo, stated: 'Our second quarter results reflect steady progress under the Company's operational turnaround plan, with improved production volumes, higher recoveries, and enhanced mine access to support future production. While we are encouraged by these developments, we know there is still more work ahead to further reduce costs, improve efficiencies and increase margins across our operations. We remain focused on safely executing our plan to meet our production and sales targets for the year, while also addressing liquidity constraints stemming from lower production in the first quarter by working closely with our suppliers and service providers.' He continued: 'In parallel, Storion Energy's new supply agreement with TerraFlow Energy and electrolyte lease for a 48 MWh vanadium flow battery deployment in Texas represent an important step in advancing Largo's investment strategy in the U.S. energy storage sector. The recently announced supply agreement with TerraFlow is expected to create a meaningful growth opportunity by leveraging Storion's battery stack development and electrolyte production capabilities as well as access to Largo Physical Vanadium's unique electrolyte leasing model, providing an additional pathway for long-term value creation for Largo through its investment in this sector.' Maracás Menchen Mine Operational and Sales Results Q2 2025 Q1 2025 Q2 2024 Total Mined – Dry Basis (tonnes) 4,261,626 3,933,242 3,216,930 Total Waste Moved – Dry Basis (tonnes) 3,775,939 3,486,628 2,648,344 Total Ore Mined (tonnes) 485,687 446,614 568,588 Ore Grade Mined – Effective Grade (%) 2 0.51 0.41 0.69 Concentrate Produced (tonnes) 89,792 53,245 115,075 Grade of Concentrate (%) 2.90 2.86 2.95 Global Recovery (%) 3 84.9 77.8 74.3 V 2 O 5 produced (Flake + Powder) (tonnes) 2,256 1,297 2,689 V 2 O 5 produced (equivalent pounds) 1 4,973,623 2,852,778 5,928,223 Total V 2 O 5 equivalent sold (tonnes) 1,807 2,046 1,841 Produced V 2 O 5 equivalent sold (tonnes) 1,684 1,892 1,713 Purchased V 2 O 5 equivalent sold (tonnes) 123 154 128 Ilmenite concentrate produced (tonnes) 8,149 6,162 8,625 Ilmenite concentrate sold (tonnes) 6,024 8,647 12,261 Q2 2025 Production and Sales Overview V₂O₅ production was 2,256 tonnes in Q2 2025, with monthly output of 481 tonnes in April, 835 tonnes in May, and 940 tonnes in June. The global recovery 3 rate averaged 84.9% for the quarter, increasing steadily from 79.3% in April to 88.0% in June. The Company continued to implement key operational measures under its turnaround plan during Q2 2025. Mine pushback activities and roadway improvements were prioritized to secure access to larger benches on the 190/180 levels, including the development of a new eastern access to the Campbell Pit. These actions are expected to reduce average haul distances and provide independent access to deeper portions of the mine. The Company's mining contractor delivered improved drilling, blasting, load/haul performance, and bench preparation during the quarter, supported by enhanced road and access maintenance. With the wider open bench area now accessible on the 180 level, larger mining fronts and production blasts are enabling increased production and improved grades. Completion of this development work is expected to support consistent access and achievement of future production targets. Total material mined (dry basis) increased by 32% in Q2 2025 to 4.3 million tonnes, compared to 3.2 million tonnes in Q2 2024, and rose 8% from Q1 2025 (3.9 million tonnes). Total ore mined in Q2 2025 was 485,687 dry tonnes, representing a 15% decrease from the 568,588 tonnes mined in Q2 2024 but a 9% increase from the 446,614 tonnes mined in Q1 2025. The effective grade of 0.51% was 26% lower year-over-year but 24% higher than Q1 2025 (0.41%). Total waste moved increased by 43% in Q2 2025 to 3.8 million tonnes, compared to 2.7 million tonnes in Q2 2024, and was 8% higher than the 3.5 million tonnes moved in Q1 2025. V 2 O 5 equivalent sales were 1,807 tonnes in Q2 2025, including 123 tonnes of purchased material, representing a 2% decrease compared to 1,841 tonnes sold in Q2 2024. Ilmenite sales were 6,024 tonnes in Q2 2025 vs.12,261 tonnes in Q2 2024. The year-over-year decrease in sales primarily reflects lower production volumes in Q1 2025, as sales generally align with production from the preceding quarter. Storion Signs Agreement to Supply Vanadium Electrolyte and Stacks for TerraFlow; Secures 48 MWh Flow Battery Electrolyte Lease Storion Energy LLC (' Storion '), a 50:50 joint venture between the Company's subsidiary, Largo Clean Energy Corp., and affiliates of Stryten Energy LLC, has signed a strategic supply agreement with TerraFlow Energy Operating LLC (' TerraFlow ') to advance the adoption of vanadium flow batteries in the United States. The collaboration will leverage Storion's ability to produce high-quality vanadium electrolyte and its expertise in stack design and manufacturing to help scale TerraFlow's skid-based architecture. Together, the companies aim to enhance performance, improve manufacturing efficiency, and deliver safe, scalable storage that meets the demands of modern power grids. Article content As part of this collaboration, Storion has also secured a vanadium electrolyte lease for TerraFlow's 48 MWh Bellville flow battery project in Texas, which, when completed, will be one of the largest flow battery installations in the state. The project will be supported by Largo Physical Vanadium Corp. (' LPV '), in which the Company holds a 65.7% interest and for which Storion acts as safekeeper of LPV's vanadium assets. LPV's unique leasing platform removes the need for customers to purchase vanadium outright, lowering upfront capital costs and making long-duration storage more cost-competitive. LPV expects to the lease to commence in early 2027, when the electrolyte is deployed. Article content The strategic supply agreement with TerraFlow is also expected to support additional flow battery deployments in the future, creating further demand for leased vanadium and strengthening Largo's participation in advancing U.S. energy resilience and the long-duration storage market. Article content Largo is a globally recognized supplier of high-quality vanadium and ilmenite products, sourced from its world-class Maracás Menchen Mine in Brazil. As one of the world's largest primary vanadium producers, Largo produces critical materials that empower global industries, including steel, aerospace, defense, chemical, and energy storage sectors. The Company is committed to operational excellence and sustainability, leveraging its vertical integration to ensure reliable supply and quality for its customers. Article content Largo is also strategically invested in the long-duration energy storage sector through its 50% ownership of Storion Energy, a joint venture with Stryten Energy focused on scalable domestic electrolyte production for utility-scale vanadium flow battery long-duration energy storage solutions in the U.S. Article content Largo's common shares trade on the Nasdaq Stock Market and on the Toronto Stock Exchange under the symbol 'LGO'. For more information on the Company, please visit Article content This press release contains 'forward-looking information' and 'forward-looking statements' within the meaning of applicable Canadian and United States securities legislation. Forward‐looking information in this press release includes, but is not limited to, statements with respect to the timing and amount of estimated future production and sales; the future price of commodities; the effect of tariffs on the Company's sales and other business; costs of future activities and operations, including, without limitation, the effect of inflation and exchange rates; the effect of unforeseen equipment maintenance or repairs on production; the ability to produce high purity V2O5 and V2O3 according to customer specifications; the extent of capital and operating expenditures; the ability of the Company to make improvements on its current short-term mine plan; and the impact of global delays and related price increases on the Company's global supply chain and future sales of vanadium products. Article content The following are some of the assumptions upon which forward-looking information is based: that general business and economic conditions will not change in a material adverse manner; demand for, and stable or improving price of V2O5 and other vanadium products, ilmenite and titanium dioxide pigment; receipt of regulatory and governmental approvals, permits and renewals in a timely manner; that the Company will not experience any material accident, labour dispute or failure of plant or equipment or other material disruption in the Company's operations at the Maracás Menchen Mine or relating to Largo Clean Energy, specially in respect of the installation and commissioning of the EGPE project; the availability of financing for operations and development; the availability of funding for future capital expenditures; the ability to replace current funding on terms satisfactory to the Company; the ability to mitigate the impact of heavy rainfall; the reliability of production, including, without limitation, access to massive ore, the Company's ability to procure equipment, services and operating supplies in sufficient quantities and on a timely basis; that the estimates of the resources and reserves at the Maracás Menchen Mine are within reasonable bounds of accuracy (including with respect to size, grade and recovery and the operational and price assumptions on which such estimates are based); the accuracy of the Company's mine plan at the Maracás Menchen Mine; that the Company's current plans for ilmenite can be achieved; the Company's ability to protect and develop its technology; the Company's ability to maintain its IP; the competitiveness of the Company's product in an evolving market; the Company's ability to attract and retain skilled personnel and directors; the ability of management to execute strategic goals; Article content that the Company will enter into agreements for the sales of vanadium, ilmenite and TiO2 products on favourable terms and for the sale of substantially all of its annual production capacity; and receipt of regulatory and governmental approvals, permits and renewals in a timely manner. Article content Forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'occur' or 'be achieved', although not all forward-looking statements include those words or phrases. In addition, any statements that refer to expectations, intentions, projections, guidance, potential or other characterizations of future events or circumstances contain forward-looking information. Forward-looking statements are not historical facts nor assurances of future performance but instead represent management's expectations, estimates and projections regarding future events or circumstances. Forward-looking statements are based on our opinions, estimates and assumptions that we considered appropriate and reasonable as of the date such information is stated, subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Largo to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks described in the annual information form of Largo and in its public documents filed on and available on from time to time. Forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Although management of Largo has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Largo does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. Readers should also review the risks and uncertainties sections of Largo's annual and interim MD&A which also apply. Article content Article content Article content Article content Contacts Article content For further information: Article content
